Global Leading Market Research Publisher QYResearch announces the release of its latest report “Needle-Free Peptide Delivery – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Needle-Free Peptide Delivery market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Needle-Free Peptide Delivery was estimated to be worth US343millionin2025andisprojectedtoreachUS343millionin2025andisprojectedtoreachUS599 million by 2032, growing at a CAGR of 8.4% from 2026 to 2032. For pharmaceutical product managers, drug delivery R&D scientists, and peptide therapeutics developers, the core business imperative lies in adopting needle-free peptide delivery technologies that address the critical need for non-invasive or minimally invasive delivery of peptide drugs (e.g., insulin for diabetes, GLP-1 agonists for obesity (liraglutide, semaglutide), calcitonin for osteoporosis, leuprolide for prostate cancer, teriparatide for osteoporosis, desmopressin for diabetes insipidus)—solving problems of needle pain, needle phobia, infection risk, poor patient compliance, and enabling self-administration at home. Needle-free peptide delivery technologies overcome physiological barriers (stratum corneum, mucosal epithelium) and enzymatic degradation (proteases) to achieve sufficient bioavailability (typically 1-20% vs injection 100%). Core technologies: jet injectors (liquid jet stream penetrates skin, no needle) (PharmaJet, Bioject, Crossject, Antares, Zogenix, InsuJet, Medical International Technology (MIT), Akra Dermojet, TheraJect, TARI Labs, Portal Instruments), inhaler technology (pulmonary delivery, dry powder, aerosol) (MannKind (not listed)), transdermal patch technology (microneedle patch, drug-in-adhesive) (Zynerba (cannabinoids), others), electroporation (pulsed electric field enhances skin permeability), laser-powered systems (microscopic holes), and microporation (heat, radiofrequency). Applications: hospitals & clinics (supervised administration), home care (patient self-administration (diabetes, obesity, osteoporosis)), research laboratories (preclinical studies), pharmaceutical & biotech companies (drug development, formulation), and others. Key players: PharmaJet (US), Bioject Medical Technologies (US), Crossject (France), Antares Pharma (US, now part of Halozyme), Zogenix (US), Portal Instruments (US), InsuJet (Netherlands), Medical International Technology (US), Akra Dermojet (France), TheraJect (US), TARI Labs (US), Mitsubishi Tanabe, Novartis (Sandoz), Takeda, Gerresheimer (drug delivery devices).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6093391/needle-free-peptide-delivery
The Needle-Free Peptide Delivery market is segmented as below:
Zynerba Pharmaceuticals
Portal Instruments
Crossject Société Anonyme
3M
Antares Pharma
Zogenix
PharmaJet
Inovio Pharmaceuticals
Bioject Medical Technologies
Valeritas
Takeda Pharmaceutical Company
Medical International Technology
Endo International
Akra Dermojet
TheraJect
TARI Labs
InsuJet
Gerresheimer AG
Mitsubishi Tanabe Pharma Corporation
Novartis AG
Segment by Type
Jet Injectors
Inhaler Technology
Transdermal Patch Technology
Electroporation
Laser-Powered Systems
Microporation
Segment by Application
Hospitals & Clinics
Home Care
Research Laboratories
Pharmaceutical & Biotech Companies
Others
1. Market Drivers: GLP-1 Agonists (Obesity-Diabetes), Peptide Therapeutics Pipeline, and Patient Compliance
Several powerful forces are driving the needle-free peptide delivery market:
GLP-1 agonist market (semaglutide (Ozempic, Wegovy), liraglutide, tirzepatide) explosive growth – Weight loss, type 2 diabetes, cardiovascular benefits. Needle-free delivery improves patient adherence (once-weekly vs daily). Oral semaglutide (Rybelsus) need high dose.
Peptide therapeutics pipeline expansion – Calcitonin (osteoporosis), teriparatide (bone), leuprolide (prostate cancer), desmopressin (nocturia). Biologics.
Needle phobia (~25% population) – Fear of injection. Non-compliance. Needle-free alternatives increase acceptance.
Recent market data (December 2025): According to Global Info Research analysis, jet injectors dominate needle-free peptide delivery with approximately 50% revenue share (insulin, vaccines, GLP-1). Transdermal patches 20% share. Inhaler technology 15% share. Electroporation 5%. Laser 3%. Microporation 5%. Others 2%. Home care (diabetes, osteoporosis self-injection) largest application (40% share). Hospitals & clinics (vaccines, supervised) 30% share. Pharma & biotech (R&D) 20% share. Research labs 10% share. North America largest market (45% share). Europe 30% share. Asia-Pacific 20% share.
2. Peptide Delivery Technologies
| Technology | Mechanism | Depth | Volume | Bioavailability (Peptide) | Pain | Cost | Share |
|---|---|---|---|---|---|---|---|
| Jet Injector | High-pressure liquid jet | Intramuscular/subcutaneous | 0.1-1.0 mL | 80-95% | Low | Medium | ~50% |
| Inhaler (Pulmonary) | Dry powder/aerosol | Lung (alveoli) | Low | 10-50% | Painless | High | ~15% |
| Transdermal Patch | Drug diffusion, microneedle | Epidermis/dermis | Low (mg) | 5-30% | Low | Medium | ~20% |
| Electroporation | Electrical pulses | Dermis | Low | 10-40% | Moderate | High | ~5% |
Key specifications: Delivery mechanism, pressure (jet injector 2000-4000 psi). Nozzle dimension. Needle-free syringe (disposable). Dose accuracy. Drug viscosity compatibility. Peptide molecular weight limit (MW <5 kDa for transdermal, higher for injector). Enzyme inhibition (protease, peptidase). Absorption enhancers (chemical, physical). Device design (reusable, single-use). Regulatory (FDA, CE) approval.
Exclusive observation (Global Info Research analysis): Needle-free peptide delivery market is dominated by jet injector technology (PharmaJet (Stratis, Tropis), Bioject (Biojector 2000), Crossject (Zeneo), Antares (Vision), InsuJet (insulin), Medical International Technology) . Transdermal patch (Zynerba (cannabinoid), but peptide not viable large MW). Inhaler (MannKind (Afrezza insulin) but not blockbuster). Oral delivery (Rybelsus (semaglutide), but low bioavailability). Needle-free market challenged by bioavailability.
User case – GLP-1 injection (December 2025): Diabetic patient (US) uses needle-free jet injector (InsuJet, PharmaJet) to administer liraglutide (Victoza, Saxenda) subcutaneously daily. No needle, less pain, higher compliance vs pen injector.
User case – needle-free insulin (January 2026): Crossject’s Zeneo (needle-free autoinjector) for emergency (epinephrine, not peptide). Insulin study.
3. Technical Challenges
Low bioavailability (needle-free vs injection) – Skin barrier, enzymatic degradation. Only 1-20% bioavailability vs 100% subcutaneous. Higher dose required (increased cost).
Dosing accuracy and reproducibility – Jet injector variability (skin thickness, injection angle, tissue tension). Dose variation.
Technical difficulty – needle-free for high viscosity peptide formulations: High concentration peptides (viscosity). Jet injector nozzle clogging.
Technical development (October 2025): Portal Instruments (US) developed needle-free jet injector (pulse wave, adjustable) for high viscosity biologics (peptides). Prefilled cartridge.
4. Competitive Landscape
Key players include: Zynerba (US – transdermal), Portal Instruments (US), Crossject (France – Zeneo), 3M (US – transdermal microprojection), Antares Pharma (US – Vibex), Zogenix (US), PharmaJet (US), Inovio (US – electroporation), Bioject (US), Valeritas (US – V-Go, discontinued), Takeda (Japan), Medical International Technology (US), Endo International (US), Akra Dermojet (France), TheraJect (US), TARI Labs (US), InsuJet (Netherlands), Gerresheimer (Germany), Mitsubishi Tanabe (Japan), Novartis (Switzerland). Pharmajet, Bioject, Crossject leaders.
Regional dynamics: North America (PharmaJet, Bioject, Antares, Portal). Europe (Crossject, Akra, InsuJet). Asia-Pacific (Mitsubishi Tanabe, Takeda). Needle-free niche, not replaced standard injection.
5. Outlook
Needle-free peptide delivery market will grow at 8.4% CAGR to US$599 million by 2032, driven by GLP-1 agonist market, peptide therapeutics pipeline, and patient compliance demand. Technology trends: oral peptide delivery (Rybelsus, enprostil), microneedle patches (dissolvable, wearable), and closed-loop insulin delivery (needle-free pump). Asia-Pacific growth 9-10% CAGR. Needle-free adoption limited by bioavailability (cost) but patient preference.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
